Ondansetron Orally Disintegrating Tablets

SOL #: SPE2D2-25-R-0018Solicitation

Overview

Buyer

DEPT OF DEFENSE
Defense Logistics Agency
DLA TROOP SUPPORT
PHILADELPHIA, PA, 19111, United States

Place of Performance

Place of performance not available

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

Drugs And Biologicals (6505)

Set Aside

No set aside specified

Timeline

1
Posted
Aug 7, 2025
2
Last Updated
Feb 23, 2026
3
Submission Deadline
Mar 23, 2026, 7:00 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

The Defense Logistics Agency (DLA) Troop Support has issued a Solicitation (SPE2D2-25-R-0018) for the procurement of Ondansetron Orally Disintegrating Tablets (ODT) in various strengths. This effort aims to establish a national supply source for the Department of Defense (DoD), Department of Veterans Affairs (VA), Indian Health Service (IHS), and Bureau of Prisons (BoP) through the Pharmaceutical Prime Vendor (PPV) program. Proposals are due March 23, 2026, at 3:00 PM EST.

Scope of Work

This solicitation seeks to procure Ondansetron ODT in 4 MG (30 count) and 8 MG (10 and 30 count) bottles. Key requirements include:

  • Packaging: Unit of use, child-proof closures, minimum 100cc volume cylindrical bottles (minimum 5.75" circumference), with specific label dimensions (5.25" x 2" plus 0.5" for barcode/expiration). Amendment 0001 clarified that "Bottles" and/or "Blister Packaging" are acceptable, and the "Schedule of Supplies" details estimated quantities for a base year and four option years for each item.
  • Labeling: Bar code labeling at unit-of-use level, conforming to GS1-128 or HIBCC standards.
  • Product Registration: Must be registered with RXNorm, First Data Bank, and Medi-Span prior to contract performance.
  • Regulatory Compliance: Offerors must possess FDA approval (NDA, ANDA, or Biologic License) by the closing date, and manufacturing facilities must have acceptable cGMP status.

Contract & Timeline

  • Type: Firm-fixed-price requirements contract.
  • Period of Performance: One base year with four option years, for a maximum of five years.
  • Set-Aside: UNRESTRICTED.
  • NAICS Code: 325412, Size Standard: 1300 employees.
  • Response Due: March 23, 2026, 3:00 PM EST (extended by Amendment 0002).
  • Published Date: February 23, 2026 (latest amendment).

Submission & Evaluation

  • Submission Method: Electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS).
  • Evaluation Criteria: Lowest Price Technically Acceptable (LPTA). Award will be made to the responsible offeror with a technically acceptable proposal and the lowest evaluated aggregate price.
  • Proposal Structure: Must include a Non-Price Proposal (Volume 1) and a Price Proposal (Volume 2).
  • Certifications: Offerors must complete representations and certifications electronically via SAM.gov.

Additional Notes

A reverse auction may be used for price discussions. Offerors must enter into business-to-business agreements with DLA and VA PPV contractors. Contract prices may be adjusted by distribution fees.

People

Points of Contact

Jason C. WraySECONDARY

Files

Files

Download
Download
Download
Download

Versions

Version 4Viewing
Solicitation
Posted: Feb 23, 2026
Version 3
Solicitation
Posted: Jan 29, 2026
View
Version 2
Solicitation
Posted: Jan 22, 2026
View
Version 1
Pre-Solicitation
Posted: Aug 7, 2025
View
Ondansetron Orally Disintegrating Tablets | GovScope